Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for misleading statements made during the Class Period from May 9, 2024, to May 8, 2025, which allegedly resulted in investor losses [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Iovance made false or misleading statements regarding the initiation of patient treatments at newly authorized treatment centers (ATCs) [3]. - It is alleged that Iovance's sales team and ATCs faced challenges in effectively identifying and selecting patients, leading to higher patient drop-off rates [3]. - These operational issues reportedly resulted in increased costs and reduced revenue, as ATCs could not keep pace with product manufacturing [3]. - The lawsuit contends that the positive statements made by Iovance regarding its business and outlook were materially misleading or lacked a reasonable basis [3]. Group 2: Investor Actions - Investors who purchased Iovance securities during the Class Period have until July 14, 2025, to file a lead plaintiff motion [1]. - The Portnoy Law Firm is offering complimentary case evaluations to discuss options for recovering losses [2][4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Iovance Biotherapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 14, 2025, for a class action lawsuit [1][2] Group 1: Class Action Details - The class action lawsuit claims that Iovance made false and misleading statements regarding the effectiveness of new Authorized Treatment Centers (ATCs) in treating patients with Amtagvi, leading to higher costs and lower revenue [3] - Investors who purchased Iovance securities between May 9, 2024, and May 8, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4] - The firm has been recognized for its achievements in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements since 2013 [4]

Core Viewpoint - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin amid commercial challenges and a class-action lawsuit related to its flagship drug Amtagvi [1][2][3]. Group 1: Leadership Transition - CFO Jean-Marc Bellemin will resign effective July 10, 2025, to pursue other endeavors, having held the position since November 2020 [1][2]. - The company has not yet named a successor for the CFO role, creating uncertainty during a challenging period [2]. Group 2: Commercial Challenges - Iovance's first-quarter sales for Amtagvi significantly underperformed expectations, leading to a downward revision of full-year revenue projections [3]. - The company's stock price fell over 44%, from $3.17 on May 8, 2025, to $1.75 by the close of trading on May 9, 2025, reflecting investor concerns about commercial execution [7]. Group 3: Legal Issues - Iovance is facing a class-action lawsuit alleging securities fraud related to the company's portrayal of its authorized treatment centers (ATCs) and their role in driving demand for Amtagvi [4][5]. - The lawsuit claims that ATCs experienced delays in initiating treatments and inefficiencies in patient selection, leading to higher patient drop-off rates [5][6]. - Hagens Berman is investigating the allegations to determine if the company's public statements were consistent with internal realities [8].

Core Insights - Iovance Biotherapeutics, Inc. is facing potential shareholder litigation due to undisclosed operational issues affecting its T cell immunotherapy product, Amtagvi [1] - The company reported a significant decline in quarterly product revenue and drastically reduced its full-year revenue guidance for 2025 [2] - Following the financial results announcement, Iovance's stock price experienced a dramatic drop of approximately 44.8% in one day [3] Financial Performance - Iovance's total product revenue for Q1 2025 was $49.3 million, down from $73.7 million in the previous quarter, indicating a decline of about 33% [2] - The full fiscal year 2025 revenue guidance was revised from a range of $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [2] Stock Market Reaction - On May 8, 2025, Iovance's stock closed at $3.17 per share, but fell to $1.75 per share on May 9, 2025, marking a decline of about 44.8% [3]

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the company's performance and treatment timelines for its melanoma drug Amtagvi [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. Product Launch and Issues - Iovance launched its key melanoma treatment, Amtagvi, in February 2024, but has faced challenges with its authorized treatment centers (ATCs) [3]. - The company claimed that its ATCs would drive demand for Amtagvi; however, there were long timelines for patient treatment initiation and ineffective patient identification, leading to high patient drop-offs [4]. Financial Performance - On May 8, 2025, Iovance reported disappointing financial results for the first quarter of 2025 and revised its full-year 2025 revenue guidance downward due to "recent launch dynamics" and high patient drop-off rates [5]. - Following the announcement, Iovance's stock price fell over 44%, from $3.17 per share to $1.75 per share within a day [6].

Core Viewpoint - Iovance Biotherapeutics, Inc. is facing a class action lawsuit due to allegations of providing misleading statements about its growth potential and financial performance, leading to significant stock price decline [1][3]. Group 1: Allegations and Financial Performance - The class period for the lawsuit is from May 9, 2024, to May 8, 2025 [3]. - Allegations include that Iovance made overwhelmingly positive statements while concealing material adverse facts about its ability to generate demand for its treatments [3]. - On July 25, 2024, Iovance announced a reduction in revenue guidance for fiscal year 2024, attributing it to maintenance issues, lower-than-expected Proleukin sales, and a variable pace of treatment initiation [3]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.795% in one day [3]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 14, 2025, to participate in potential recovery [4]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].

Core Insights - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin, effective July 10, 2025, amid commercial challenges and a class-action lawsuit [1][2][3] Group 1: Leadership Changes - CFO Jean-Marc Bellemin's resignation is effective July 10, 2025, and he is leaving to pursue other endeavors [1][2] - Bellemin's departure aligns with the terms of his executive employment agreement, and a successor has not yet been named [2] Group 2: Commercial Performance - Iovance's flagship drug, Amtagvi, has faced significant commercial setbacks, with first-quarter sales underperforming Wall Street expectations [3] - The company has revised its full-year revenue projections downward, leading to a downgrade from UBS [3] Group 3: Legal Challenges - Iovance is defending against a class-action securities fraud lawsuit related to its portrayal of authorized treatment centers (ATCs) crucial for Amtagvi's administration [4][5] - The lawsuit alleges discrepancies between the company's claims about ATC operations and the actual performance, including delays in patient treatment initiation and high patient drop-off rates [5][6] Group 4: Market Reaction - Following the disclosure of disappointing first-quarter results and revised revenue guidance, Iovance's stock fell over 44%, from $3.17 per share to $1.75 per share within a day [6][7] - The market's swift reaction reflects investor concerns regarding the company's commercial execution and the accuracy of its operational updates [7]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Iovance Biotherapeutics, Inc. due to allegations of false and misleading statements regarding the company's growth potential and operational capabilities [3][5]. Group 1: Legal Investigation and Class Action - A federal securities class action has been filed against Iovance, with a deadline of July 14, 2025, for investors to seek the role of lead plaintiff [3]. - Investors who suffered losses exceeding $100,000 in Iovance between August 8, 2024, and May 8, 2025, are encouraged to contact the law firm for discussions on their legal rights [1][3]. Group 2: Financial Performance and Stock Impact - On July 25, 2024, Iovance announced its second-quarter financial results for fiscal 2024 and reduced its revenue guidance for the full year, attributing this to maintenance issues, lower-than-expected Proleukin sales, and the variable pace of treatment initiation [6]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in just one day [6]. Group 3: Allegations Against Iovance - The complaint against Iovance alleges that the company and its executives violated federal securities laws by failing to disclose the true state of the company's growth potential and operational readiness to meet demand for its treatments [5].

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, administered at authorized treatment centers (ATCs) [3]. Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs as a driver of demand for Amtagvi, while in reality, these centers faced long timelines for patient treatment and high patient drop-off rates due to ineffective patient identification and selection [4]. - Following disappointing financial results for Q1 2025, Iovance revised its full-year 2025 revenue guidance, attributing the poor performance to slow treatment timelines and high patient drop-off rates [5]. Stock Performance - On May 8, 2025, Iovance's stock price fell over 44%, dropping from $3.17 per share to $1.75 per share the following day, in response to the negative financial news [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Iovance Biotherapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 14, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Iovance securities between May 9, 2024, and May 8, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 14, 2025 [2]. - The lawsuit alleges that Iovance made false and misleading statements regarding the effectiveness of its sales team and new Authorized Treatment Centers (ATCs), which led to higher costs and lower revenue [3]. Group 2: Allegations Against Iovance - The lawsuit claims that new ATCs faced longer timelines to begin treating patients, and the sales team was ineffective in patient identification and selection, resulting in higher patient drop-offs [3]. - These dynamics contributed to a situation where ATCs could not keep pace with manufactured products, leading to misleading positive statements about Iovance's business and operations [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including a notable settlement of over $438 million in 2019 [4].